title: Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.
abstract: The presence of p53 mutation or deletion predicts for poor response to conventional therapy in chronic lymphocytic leukemia (CLL). We sought to determine whether the humanized anti-CD52 antibody alemtuzumab was effective in this patient group. Thirty-six patients with fludarabine-refractory CLL were treated with alemtuzumab, 15 (42%) of whom had p53 mutations or deletions. Clinical responses in patients with p53 mutations, deletions, or both were noted in 6 (40%) of 15 versus 4 (19%) of 21 of patients without. The median response duration for this subset of patients was 8 months (range, 3-17 months). These data suggest that alemtuzumab may be an effective therapy for patients with CLL with p53 mutations or deletions.
authors.affiliation: Department of Pathology, Ohio State University, Columbus, OH 43210, USA.
authors.forename: Gerard
authors.initials: G
authors.lastname: Lozanski
authors.forename: Nyla A
authors.initials: NA
authors.lastname: Heerema
authors.forename: Ian W
authors.initials: IW
authors.lastname: Flinn
authors.forename: Lisa
authors.initials: L
authors.lastname: Smith
authors.forename: Jennifer
authors.initials: J
authors.lastname: Harbison
authors.forename: Jennifer
authors.initials: J
authors.lastname: Webb
authors.forename: Mollie
authors.initials: M
authors.lastname: Moran
authors.forename: Margaret
authors.initials: M
authors.lastname: Lucas
authors.forename: Thomas
authors.initials: T
authors.lastname: Lin
authors.forename: Marcy L
authors.initials: ML
authors.lastname: Hackbarth
authors.forename: John H
authors.initials: JH
authors.lastname: Proffitt
authors.forename: David
authors.initials: D
authors.lastname: Lucas
authors.forename: Michael R
authors.initials: MR
authors.lastname: Grever
authors.forename: John C
authors.initials: JC
authors.lastname: Byrd
mesh_terms: D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D004341:Drug Evaluation; D004351:Drug Resistance; D016158:Genes, p53; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011379:Prognosis; D012189:Retrospective Studies; D017384:Sequence Deletion; D016896:Treatment Outcome; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab; D014740:Vidarabine; C024352:fludarabine